Programmed cell death ligand 1 expression on monocytes is inversely correlated with tumour response to preoperative chemoradiotherapy for locally advanced rectal cancer

Tojo, Miyuki; Horie, Hisanaga; Koinuma, Koji; Miyato, Hideyo; Tsukui, Hidenori; Kaneko, Yuki; Futoh, Yurie; Kimura, Yuki; Takahashi, Katsuhiko; Saito, Akira; Ohzawa, Hideyuki; Yamaguchi, Hironori; Lefor, Alan Kawarai; Sata, Naohiro; Kitayama, Joji

doi:10.1111/codi.16167

Cited by 4 publications

(2 citation statements)

References 45 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was found that the higher the ratio of infiltrating CD8 + T cells to effector Tregs cells in tumor tissue, the better the efficacy. In addition, PD-L1 positivity, Ki-67 expression of tumor infiltrating CD8 + T cells, and CMS1 and CMS3 typing of CRC also predicted high response to chemoradiotherapy ( 75 ). In a prospective phase 2 study, all 12 patients (100%) with dMMR stage II or III rectal adenocarcinoma had a clinical complete response when treated with dostarlimab, with no evidence of tumor on imaging examination ( 76 ).…”

Section: Application Of Biomarkers In the Treatment Of Digestive Syst...mentioning

confidence: 99%

The efficacy-associated biomarkers for immune checkpoint inhibitors in gastrointestinal cancer: a literature review

Zhao,

Jin,

Zhao

et al. 2024

J Gastrointest Oncol

View full text Add to dashboard Cite

Background and Objective Immune checkpoint inhibitors (ICIs) have been widely applied and studied in the treatment of gastrointestinal (GI) cancers, and have achieved good results. However, in clinical practice, it has been observed that only some patients respond well to ICIs, and some patients may experience various degrees of adverse reactions during the treatment. Timely evaluation of the potential therapeutic effects and adverse reactions of ICIs for patients has important clinical significance. This review aimed to summarize recent progress regarding efficacy-associated biomarkers for ICIs in GI cancer. Methods The literature on ICI treatment in GI cancers was searched in the PubMed, Embase, and Cochrane Library databases for publications up to April 2023. Key Content and Findings Clinical practice and research has gradually revealed some biomarkers related to the treatment of GI cancers with ICIs, which can be roughly divided into three types: biomarkers that predict the effectiveness of ICIs treatment, biomarkers associated with resistance to ICIs, and biomarkers associated with immune related adverse events (irAEs). This review article provides a literature review on biomarkers related to the efficacy of ICIs in the treatment of GI cancers. Conclusions According to existing clinical research results, there are multiple biomarkers that can be used for predicting and monitoring the efficacy and risk of adverse events of ICIs in the treatment of digestive system malignant tumors.

show abstract

Section: Application Of Biomarkers In the Treatment Of Digestive Syst...mentioning

confidence: 99%

The efficacy-associated biomarkers for immune checkpoint inhibitors in gastrointestinal cancer: a literature review

Zhao,

Jin,

Zhao

et al. 2024

J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…The quality of circulating T-cells and monocytes has also been investigated in a limited number of studies on rectal cancer. Tojo et al assessed the presence of PD-L1 expressing monocytes in the blood of rectal cancer patients [150]. A high percentage of this subpopulation before and after CRT correlated with low T-cell counts and was significantly linked with poor response to therapy.…”

Section: Systemic Immune Responsementioning

confidence: 99%

Immune Response and Immune Checkpoint Molecules in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Review

Koukourakis

Platoni

Tiniakos

et al. 2023

CIMB

View full text Add to dashboard Cite

It is well-established that tumor antigens and molecules expressed and secreted by cancer cells trigger innate and adaptive immune responses. These two types of anti-tumor immunity lead to the infiltration of the tumor’s microenvironment by immune cells with either regulatory or cytotoxic properties. Whether this response is associated with tumor eradication after radiotherapy and chemotherapy or regrowth has been a matter of extensive research through the years, mainly focusing on tumor-infiltrating lymphocytes and monocytes and their subtypes, and the expression of immune checkpoint and other immune-related molecules by both immune and cancer cells in the tumor microenvironment. A literature search has been conducted on studies dealing with the immune response in patients with rectal cancer treated with neoadjuvant radiotherapy or chemoradiotherapy, assessing its impact on locoregional control and survival and underlying the potential role of immunotherapy in the treatment of this cancer subtype. Here, we provide an overview of the interactions between local/systemic anti-tumor immunity, cancer-related immune checkpoint, and other immunological pathways and radiotherapy, and how these affect the prognosis of rectal cancer patients. Chemoradiotherapy induces critical immunological changes in the tumor microenvironment and cancer cells that can be exploited for therapeutic interventions in rectal cancer.

show abstract